Healthcare - Biotechnology - NASDAQ - US
$ 3.125
-8.89 %
$ 201 M
Market Cap
-2.02
P/E
BALANCE SHEET
201 M
ASSETS
60.4 M
LIABILITIES
140 M
EQUITY
BALANCE SHEET DECOMPOSITION
Balance Sheet Decomposition
Inozyme Pharma, Inc.
| Current Assets | 196 M |
| Cash & Short-Term Investments | 189 M |
| Receivables | 385 K |
| Other Current Assets | 7.28 M |
| Non-Current Assets | 4.6 M |
| Long-Term Investments | 0 |
| PP&E | 2.59 M |
| Other Non-Current Assets | 2 M |
| Current Liabilities | 14.7 M |
| Accounts Payable | 1.17 M |
| Short-Term Debt | 1.82 M |
| Other Current Liabilities | 11.7 M |
| Non-Current Liabilities | 45.7 M |
| Long-Term Debt | 45.7 M |
| Other Non-Current Liabilities | 0 |
Balance Sheet
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| Cash & Cash Equivalents | 34.6 | 32.9 | 23.3 | 159.9 | 31.6 | 36.0 |
| Short Term Investments | 154.0 | 95.0 | 88.5 | 119.7 | 15.5 | 7.2 |
| Receivables | 0.4 | 0.1 | 62 K | 0.2 | 0.1 | 31 K |
| Inventory | 0 | (0.1) | 62 K | (12.4) | 0 | 0 |
| Other Current Assets | 7.3 | 3.4 | 3.5 | 3.1 | 0.2 | 73 K |
| Total Current Assets | 196.2 | 131.4 | 115.3 | 151.0 | 47.5 | 43.3 |
| PP&E | 2.6 | 3.6 | 4.4 | 2.6 | 0.3 | 0.2 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Long Term Investments | 0 | 0.4 | 0.4 | 12.2 | 0.1 | 0 |
| Other Long Term Assets | 2.0 | 3.8 | 3.4 | 3.5 | 56 K | 34 K |
| Other Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 200.8 | 139.2 | 123.5 | 169.4 | 47.9 | 43.5 |
| LIABILITIES | ||||||
| Accounts Payable | 1.2 | 2.5 | 2.4 | 3.1 | 0.9 | 1.0 |
| Short Term Debt | 1.8 | 1.6 | 1.5 | 0 | 0 | 0 |
| Other Current Liabilities | 11.7 | 10.5 | 7.8 | 6.9 | 2.3 | 1.4 |
| Total Current Liabilities | 14.7 | 14.7 | 11.6 | 10.0 | 3.2 | 2.4 |
| Long Term Debt | 45.7 | 6.0 | 2.6 | 1.3 | 0 | 0 |
| Deferred Tax Income | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities | 0 | 0.1 | 0 | 0 | 0 | 55.0 |
| Total Liabilities | 60.4 | 20.8 | 14.3 | 11.3 | 81.2 | 57.4 |
| EQUITY | ||||||
| Common Stock | 6 K | 4 K | 2 K | 2 K | 1 K | 1 K |
| Retained Earnings | (285.9) | (214.8) | (147.7) | (91.1) | (34.7) | (14.9) |
| Other Accumulative Comprehensive Income/Loss | 41 K | (0.2) | 18 K | 2 K | 5 K | 2 K |
| Total Equity | 140.5 | 118.6 | 109.3 | 158.1 | (33.2) | (13.9) |
| Total Liabilities and Equity | 200.8 | 139.4 | 123.5 | 169.4 | 47.9 | 43.5 |
| SHARES OUTSTANDING | ||||||
| Common Shares Outstanding | 51.8 | 37.8 | 23.6 | 23.4 | 15.2 | 15.1 |